The Global Hashimoto’s Thyroiditis Drug Market is primarily driven by the growing prevalence of autoimmune diseases and the increasing awareness regarding Hashimoto's thyroiditis treatment. Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis, is the most common cause of hypothyroidism. It is an autoimmune disease where the body's immune system attacks the thyroid gland, leading to inflammation and damage over time.
Common symptoms of Hashimoto's thyroiditis include fatigue, weight gain or difficulty losing weight, constipation, feeling cold, dry skin, puffy face, joint and muscle pain, heavy periods, headaches, hair loss, depression, irritability, and memory problems. The treatment for Hashimoto's thyroiditis generally involves thyroid hormone replacement therapy and monitoring of thyroid levels to manage symptoms.
The Global Hashimoto’s Thyroiditis Drug Market is estimated to be valued at US$ 2.18 BN in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the Global Hashimoto’s Thyroiditis Drug Market are AbbVie Inc., Merck & Co., Allergan., Amneal Pharmaceuticals., Lannett Company, Mylan Pharmaceuticals, Pfizer, Akorn Pharmaceuticals, Acella Pharmaceuticals, Jerome Stevens Pharmaceuticals and Other Prominent Players. Rising prevalence of autoimmune disorders such as Graves' disease and Type 1 diabetes is expected to drive the demand for Hashimoto's thyroiditis drugs during the forecast period. Technological advancements in novel drug delivery systems and drug formulations are anticipated to provide growth opportunities in the market.
Market Trends
Increasing awareness initiatives by key players and government organizations regarding diagnosis and treatment of Hashimoto's thyroiditis is expected to boost the global Hashimoto's Thyroiditis Drugs Market Demand. Growing demand for generic drugs due to their lower cost compared to branded drugs is expected to be one of the major trends in the global Hashimoto's thyroiditis drug market.
Market Opportunities
The key opportunities in the global Hashimoto's thyroiditis drug market include strong pipeline of drugs in clinical trials and growth potential in developing economies due to improved access to healthcare facilities. Entry of new players with innovative drug delivery technologies such as sustained release capsules and subcutaneous implants can provide high growth opportunities over the forecast period.
Impact of COVID-19 on Global Hashimoto’s Thyroiditis Drug Market growth
The COVID-19 pandemic has significantly impacted the growth of the Global Hashimoto’s Thyroiditis Drug Market. Major challenges faced were disruptions in supply chain and restrictions on non-essential healthcare procedures. During the initial months of the pandemic, the focus of healthcare systems shifted towards treatment of COVID-19 patients which resulted in postponing of routine appointments and diagnostic/screening activities for other diseases including Hashimoto’s Thyroiditis. This led to reduced demand for drugs used for treatment of Hashimoto’s Thyroiditis during 2020-2021.
With lifting of lockdowns and resumption of regular healthcare services from 2022, the market is expected to recover gradually. However, continued social distancing practices are likely to keep the market growth below pre-pandemic levels until late 2022 or 2023. Telehealth and home delivery options adopted by pharmaceutical companies help sustain access to drugs required for management of chronic conditions like Hashimoto’s Thyroiditis during the pandemic. Initiatives are also being taken to educate patients about importance of adherence to prescribed treatment regimen to prevent exacerbation of symptoms during these challenging times.
As the pandemic situation stabilizes globally with increased vaccination rates, the market is projected to pick up pace supported by resumption of normal healthcare procedures, screening camps and awareness programs regarding early diagnosis and management of Hashimoto’s Thyroiditis.However, long term impact of COVID-19 on prevalence of autoimmune thyroid disorders needs to be monitored.
Geographical concentration of Global Hashimoto's Thyroiditis Drug Market
In terms of value, North America dominates the Global Hashimoto’s Thyroiditis Drug Market owing to developed healthcare infrastructure and rising awareness about thyroid disorders. The United States accounts for the major share of the regional market supported by favourable reimbursement policies and presence of major pharmaceutical players.
Asia Pacific is identified as the fastest growing regional market for Hashimoto’s Thyroiditis drugs. Factors such as increasing healthcare expenditures, large patient pool, growing geriatric population, and rising incidence of thyroid disorders drive the market growth in Asia Pacific countries especially China and India. Additionally, improved access to diagnosis and treatment due to expansion of healthcare facilities in rural regions supplements the regional market expansion.
Get More Insights on Hashimoto's Thyroiditis Drug Market
Hypothyroidism is a thyroid hormone deficiency.
The most effective and efficient way to hypothyroidism diagnosis is by measuring the thyroid-stimulating hormone (TSH) level in your blood, which will be high if you have the disease.
At the same time, the thyroid hormones, T4 and T3, will be low Some other tests may be performed to determine the cause of hypothyroidism, including measuring thyroid antibody levels
